logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Reports Positive Results From Study On Cancer Drug

Bristol-Myers Squibb Company (BMY) Saturday said an experimental drug showed positive results in patients suffering from melanoma, kidney cancer and lung cancer in a preliminary clinical trial.

Results of the Phase-I study on anti-PD-1 or BMS-936558 in patients with previously-treated non small-cell lung cancer, metastatic melanoma and renal cell carcinoma were encouraging as they showed improvement in patients. The clinical trial added to the understanding of the potential of immuno-oncology as a therapeutic approach in the treatment of cancer, the pharmaceutical firm said.

"Immuno-oncology is a prioritized area of research and development at Bristol-Myers Squibb and we plan to initiate registrational studies for anti-PD-1 in non small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma," Brian Daniels, senior vice president of Global Development and Medical Affairs t Bristol-Myers Squibb, said.

Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Anglo-Dutch oil giant Royal Dutch Shell plans to cut 2,200 more jobs, as the company continues to face lower oil prices, media reported Wednesday citing an emailed statement. The latest round of cuts would bring the total job cuts this year to at least 5,000 globally. In the U.K. and Ireland, the company plans to reduce staff working in exploration and production by 475. Tiffany & Co. (TIF) reported first-quarter net earnings of $87 million, or $0.69 per share compared to $105 million, or $0.81 per share, in the prior year. The company noted that its first-quarter results included a tax benefit of $0.05 per share related to the settlement of a tax examination. On average,... Shares of Marks & Spencer Group plc were losing around 8 percent in the early morning trading in London, after the retailer reported lower profit in its fiscal 2016, hurt mainly by weak results at clothing & Home segment and lower UK LFL sales. Looking ahead, the company warned about profit, and said it sees a similar sales trend in fiscal 2017.
comments powered by Disqus
Follow RTT